CMS-121

CMS-121 is a synthetic small molecule of the flavonoid class, developed as a neuroprotective drug candidate for Alzheimer's disease and other age-associated neurodegenerative conditions ^[1]. Chemically it is a derivative of fisetin, a naturally occurring flavonol found in strawberries and other plants that shows antioxidant, anti-inflammatory, and geroprotective activity but suffers from poor metabolic stability. Researchers at the Salk Institute for Biological Studies systematically modified the fisetin scaffold to improve its drug-like properties, generating a library of roughly 160 synthetic derivatives, from which CMS-121 was selected for its potency and favorable pharmacology ^[3].

The compound emerged from a cell-based phenotypic screening strategy built to protect against oxytosis and ferroptosis, a non-apoptotic regulated cell death pathway increasingly linked to aging and dementia ^[1]. Rather than aiming at a single classical Alzheimer's target such as amyloid beta, CMS-121 was optimized around age-related changes in brain physiology, an approach its developers describe as addressing the biology of aging itself ^[2]. In preclinical work it has been evaluated in transgenic and rapidly aging mouse models of Alzheimer's disease, in models of Huntington's disease, and in the setting of the metabolic complications of diabetes ^[1][2][3].

CMS-121 is an investigational agent and is not an approved drug; it is used in laboratory and preclinical research, and toxicology testing supported an Investigational New Drug clearance that opened the path toward human trials ^[1]. Beyond neuroscience, the same molecule is employed in cell biology as a pharmacological inhibitor of acetyl-CoA carboxylase 1, where it serves as a research tool to probe fatty acid synthesis and lipid metabolism ^[4][5]. It is supplied as a research chemical in solid or solution form and is not marketed as a dietary supplement.

Regulatory status: CMS-121 is an unapproved investigational drug. It holds an FDA IND, which is permission to run trials, not any form of approval. It is not approved by the FDA, EMA or any other regulator, for any indication, in any country. It has completed Phase 1 only; as of mid-2026 it has not entered Phase 2, and long-term toxicology is still running under NIA funding (grants R44AG085775 and U01AG084549 to Virogenics). It is not a controlled or scheduled substance. It is sold only as a laboratory research reagent (CAS 1353224-53-9, UNII BW9P9F8JEY), not as a supplement, and it is not intended or labelled for human consumption.

WADA: CMS-121 is not named individually on the Prohibited List; as a pharmacological substance with no regulatory approval for human therapeutic use it would fall under category S0, non-approved substances, which is prohibited at all times in and out of competition. Athletes should treat it as banned. Known adverse effects: the Phase 1 reported that the majority of treatment-emergent adverse events were mild in severity and that single doses to 1800 mg and 7 days at 900 mg/day were generally well tolerated.

Beyond that sentence the safety picture is genuinely unknown. No individual adverse event, no frequency table, no maximum tolerated dose and no QTc number could be retrieved: ClinicalTrials.gov has no results posted for NCT05318040, the preprint full text is not in PubMed Central and medRxiv blocks automated retrieval. Cardiac monitoring was clearly a concern to the investigators, since the trial excluded anyone with QT-prolongation risk factors and made QTc a secondary endpoint, and the preprint title flags cardiodynamics; the actual finding is not publicly readable.

Interactions: none have been studied. The trial barred all CYP and P-glycoprotein inducers including St John's wort, all QT-prolonging drugs, and all other medicines, herbals and vitamin supplements, which signals unresolved interaction risk rather than established safety. No data exist in pregnancy, in children, in liver or kidney impairment, or beyond 7 days of continuous use in humans.

CMS-121 was created at the Salk Institute for Biological Studies in California in the laboratories of David Schubert and Pamela Maher, whose group has long pursued drugs for age-related brain disease by screening for protection against oxytosis, a non-apoptotic, oxidative form of cell death, rather than against a single disease protein. Starting from the plant flavonol fisetin, which showed neuroprotective and memory-preserving activity, the team synthesized and screened roughly 160 derivatives, selecting CMS-121 as the lead for its potency, brain penetration, and efficacy in Alzheimer's disease models.

Later work by Currais, Maher, and colleagues identified an unexpected target, the fatty-acid-synthesis enzyme acetyl-CoA carboxylase 1, tying the compound's benefits to cellular lipid metabolism and mitochondrial health. Having cleared Investigational New Drug review, CMS-121 advanced toward Phase 1 evaluation in healthy volunteers, an uncommon milestone for a geroprotective candidate. It is now also used by independent laboratories as a specific pharmacological inhibitor of acetyl-CoA carboxylase 1.

CMS-121 has built a strong reputation among aging researchers as one of the more scientifically credible geroprotective drug candidates, and the reasons are genuinely compelling. Rather than chasing a single disease protein, it targets a shared metabolic and oxidative node of brain aging, and across an unusually wide range of preclinical models, spanning Alzheimer's disease, Huntington's disease, diabetes, and even normal aging, it has preserved learning and memory, curbed neuroinflammation, and limited the runaway lipid damage of the ferroptosis pathway.

Its mechanism is elegant and well-defined, raising cellular acetyl-CoA and promoting a memory-supporting epigenetic mark, and the fact that other laboratories now adopt it as a reliable ACC1 inhibitor is a quiet vote of confidence in its specificity. That it has reached human Phase 1 testing sets it apart from the many aging compounds that never leave the mouse. Honesty is still warranted; it remains an experimental, early-stage molecule, and its benefits in people have yet to be demonstrated.